Nurix Highlights Oncology and Immunology Degrader Pipeline Progress

Nurix Therapeutics announced new preclinical data from multiple oncology programs at the American Association for Cancer Research Annual Meeting 2026 and outlined progress across its immunology and inflammation pipeline. The updates included data on NRX-0305, NX-1607, NX-3911, bexobrutideg and an IRAK4 degrader, with planned clinical and regulatory milestones this year.

At the AACR Annual Meeting 2026, the company said the presentations highlighted continued progress across its oncology pipeline, including programs targeting pan-mutant BRAF, CBL-B and Aurora Kinase A, as well as a featured AACR Advances session presentation highlighting the broader scientific progress and clinical translation of targeted protein degradation. In a poster presentation, NRX-0305 was described as an orally bioavailable, CNS penetrant pan-mutant BRAF degrader that achieves dose-proportional pharmacokinetics across plasma, tumor, and brain, enabling robust degradation of mutant BRAF and downstream pathway inhibition.

In a BRAF inhibitor-resistant melanoma brain metastasis patient-derived xenograft model, NRX-0305 significantly extended survival versus both vehicle and dabrafenib, delivering a 142% increase in lifespan, compared with approximately 12% for the approved BRAF inhibitor. In preclinical tumor models, the program showed activity across 14 PDX models spanning Class 1 treatment-resistant, Class 2, and Class 3 BRAF mutations. Combination of NRX-0305 with MEK inhibitors or anti-EGFR therapy enhanced tumor regressions in Class 2 and drove complete responses in Class 1 and 3 models.

For CBL-B, the company reported discovery and characterization of novel intramolecular glue inhibitors targeting the E3 ubiquitin ligase. Through structure-guided optimization, this series was advanced to NX-1607, described as a potent and selective CBL-B inhibitor with sub-nanomolar binding affinity. In preclinical studies, NX-1607 enhanced T cell activation, as evidenced by increased IL-2 and IFN-γ secretion in response to TCR stimulation.

In immunology and inflammation, the company said targeted protein degraders remove the entire target protein and can address non-enzymatic scaffolding signaling, while also targeting proteins that are difficult for small molecules to inhibit. The STAT6 degrader NX-3911, partnered with Sanofi, is expected to enter an IND this year. In high-resolution global proteomics experiments in normal human immune cells, STAT6 was the only protein degraded at clinically relevant concentrations, and other STAT family members did not shift. The company also said STAT6 degradation in cells occurs within minutes and that oral dosing studies in multiple animal species through primates showed rapid, potent, and complete STAT6 degradation.

Nurix is also advancing the BTK degrader bexobrutideg in a tablet formulation in Phase 1 MAD studies aimed at autoimmune, dermatology and neurology uses, with Phase 1 data planned this year. Its IRAK4 degrader, partnered with Gilead, was described as showing superior tissue penetration, especially in skin, and no observed QT issues versus a competitor.